dc.contributor.author | Wong, YNS | |
dc.contributor.author | Joshi, K | |
dc.contributor.author | Khetrapal, P | |
dc.contributor.author | Ismail, M | |
dc.contributor.author | Reading, JL | |
dc.contributor.author | Sunderland, MW | |
dc.contributor.author | Georgiou, A | |
dc.contributor.author | Furness, AJS | |
dc.contributor.author | Ben Aissa, A | |
dc.contributor.author | Ghorani, E | |
dc.contributor.author | Oakes, T | |
dc.contributor.author | Uddin, I | |
dc.contributor.author | Tan, WS | |
dc.contributor.author | Feber, A | |
dc.contributor.author | McGovern, U | |
dc.contributor.author | Swanton, C | |
dc.contributor.author | Freeman, A | |
dc.contributor.author | Marafioti, T | |
dc.contributor.author | Briggs, TP | |
dc.contributor.author | Kelly, JD | |
dc.contributor.author | Powles, T | |
dc.contributor.author | Peggs, KS | |
dc.contributor.author | Chain, BM | |
dc.contributor.author | Linch, MD | |
dc.contributor.author | Quezada, SA | |
dc.date.accessioned | 2020-08-25T15:41:48Z | |
dc.date.issued | 2018-11-05 | |
dc.identifier.citation | The Journal of experimental medicine, 2018, 215 (11), pp. 2748 - 2759 | |
dc.identifier.issn | 0022-1007 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/4008 | |
dc.identifier.eissn | 1540-9538 | |
dc.identifier.doi | 10.1084/jem.20181003 | |
dc.description.abstract | Despite the advances in cancer immunotherapy, only a fraction of patients with bladder cancer exhibit responses to checkpoint blockade, highlighting a need to better understand drug resistance and identify rational immunotherapy combinations. However, accessibility to the tumor prior and during therapy is a major limitation in understanding the immune tumor microenvironment (TME). Herein, we identified urine-derived lymphocytes (UDLs) as a readily accessible source of T cells in 32 patients with muscle invasive bladder cancer (MIBC). We observed that effector CD8+ and CD4+ cells and regulatory T cells within the urine accurately map the immune checkpoint landscape and T cell receptor repertoire of the TME. Finally, an increased UDL count, specifically high expression of PD-1 (PD-1hi) on CD8+ at the time of cystectomy, was associated with a shorter recurrence-free survival. UDL analysis represents a dynamic liquid biopsy that is representative of the bladder immune TME that may be used to identify actionable immuno-oncology (IO) targets with potential prognostic value in MIBC. | |
dc.format | Print-Electronic | |
dc.format.extent | 2748 - 2759 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | ROCKEFELLER UNIV PRESS | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-sa/4.0 | |
dc.subject | CD4-Positive T-Lymphocytes | |
dc.subject | CD8-Positive T-Lymphocytes | |
dc.subject | Urine | |
dc.subject | Humans | |
dc.subject | Lymphocyte Count | |
dc.subject | Female | |
dc.subject | Male | |
dc.subject | Urinary Bladder Neoplasms | |
dc.subject | Tumor Microenvironment | |
dc.title | Urine-derived lymphocytes as a non-invasive measure of the bladder tumor immune microenvironment. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2018-09-05 | |
rioxxterms.versionofrecord | 10.1084/jem.20181003 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by-nc-sa/4.0 | |
rioxxterms.licenseref.startdate | 2018-11 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | The Journal of experimental medicine | |
pubs.issue | 11 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.publication-status | Published | |
pubs.volume | 215 | |
pubs.embargo.terms | Not known | |
dc.contributor.icrauthor | Furness, Andrew | |
dc.contributor.icrauthor | Feber, Andrew | |